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Duplex ultrasound as the sole long-term
surveillance method post-endovascular aneurysm
repair: A safe alternative for stable aneurysms
Rabih A. Chaer, MD, Anna Gushchin, BS, Robert Rhee, MD, Luke Marone, MD, Jae S. Cho, MD,
Steven Leers, MD, and Michel S. Makaroun, MD, Pittsburgh, Pa
Objective: Long-term surveillance with computed tomography (CT) after endovascular aneurysm repair (EVAR) increases
both cost and risk. The purpose of this study was to evaluate the safety of an alternative follow-up modality with color
flow duplex ultrasound scanning (CDU) as the sole method of imaging.
Methods: In 2003, we initiated a new follow-up (FU) schedule with yearly CDU as the sole imaging method for selected
patients. Indications included a residual sac of less than 4 cm, expanded later to stable sac size for more than 2 years. A
stable type II endoleak was not a contraindication. CT scans were obtained selectively-based on suspicious findings of a
new endoleak or enlarging sac on CDU. The records of all patients with at least 1 year FU under this schedule were
reviewed.
Results:One hundred eighty-four patients were followed with CDU only for 1 to 4 years for a mean of 24 13 months.
The new schedule was initiated at a mean of 34  24 months after EVAR (range 1-112 months). Twenty-three patients
had previous endoleaks that had resolved spontaneously or had been treated. During CDU FU, three new endoleaks were
detected, one with sac enlargement. All prompted CT evaluation: one type II endoleak with stable sac size could not be
identified on CT 3months later, and two distal type I endoleaks that required limb extension. All three had a prior Ancure
endograft. No ruptures or graft occlusions were noted. One abdominal aortic aneurysm (AAA) related death followed
graft explantation for infection. There were two additional deaths from malignancy and two from cardiac causes. After
the FU switch, freedom from endoleaks was 96%, and from secondary interventions 95% at 48 months by life table
method. Mean AAA diameter at baseline was 54  8 mm and decreased to 40  11 mm before the switch to CDU only
FU. At last FUmean aneurysm diameter was 39 11 mm.When the current switch criteria were applied to a consecutive
series of 200 EVAR patients, 97% would have been eligible for CDU only surveillance by 3 years postoperatively.
Conclusions:CDUonly surveillance post-EVAR is safe and can be initiated early after treatment in patients with shrinking
or stable aneurysms. This policy should result in cost savings advantage and avoid the complications associated with CT.
(J Vasc Surg 2009;49:845-50.)Endovascular aneurysm repair (EVAR) has seen rapid
diffusion as a minimally invasive alternative to open repair
and is currently widely accepted for the treatment of ab-
dominal aortic aneurysms (AAAs). Although EVAR offers
immediate advantages over open aneurysm repair with
lower perioperative mortality and morbidity,1-3 it carries
the need for lifelong surveillance for potential complica-
tions, including endoleak, change in aneurysm size, graft
migration, structural graft failure, and limb outflow impair-
ment caused by limb stenosis or occlusion. The ideal sur-
veillancemodality should be noninvasive, cheap, and repro-
ducible, with high sensitivity and specificity for the
detection of endograft related adverse events. Computed
tomography with intravenous contrast injection (CT) is
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but is associated with increased cost 4 and radiation expo-
sure.5 It could also contribute to the decline in renal
function seen after EVAR as a result of contrast nephropa-
thy.6 Color-flow duplex ultrasound scanning (CDU) can
also detect endoleaks as well as size changes over time but is
more operator dependent.7 It, however, has the distinct
advantage of being noninvasive, safer, and cheaper than CT
scans. Although several studies have evaluated the ability of
CDU to detect endoleaks and have established good cor-
relation with CT for the measurement of AAA sac diame-
ter,7 there currently is no published series of patients fol-
lowed with CDU only post-EVAR to document the safety
of this follow-up protocol The purpose of this study was
therefore to evaluate the safety of a selective policy of EVAR
follow-up with CDU as the only imaging study.
METHODS
Surveillance policy. Starting in 2003, a new follow-up
schedule for EVAR surveillance was initiated for selected
patients. Annual CDU as the sole imaging modality was
offered as early as 1 year post-EVAR for those patients with
a collapsed AAA sac 4 cm in diameter. This policy was
845
JOURNAL OF VASCULAR SURGERY
April 2009846 Chaer et alexpanded 1 year later to include patients with significant
shrinkage of the aneurysm sac to any size, or a stable
aneurysm without enlargement for 2 years whether a type
II endoleak was present or not. Patients with contrast
allergy or significant renal insufficiency (serum creatinine
2) were switched at earlier intervals depending on AAA
size and presence or absence of endoleaks. Diameter mea-
surements were defined as the minor axis of the largest axial
slice on CT. A significant shrinkage was considered to be a
minimum of 5 mm from the baseline 1-month CT. A stable
aneurysm was defined as an aneurysm with3mm increase
in diameter from baseline. Patients with enlargement of the
sac by 3 mm from the baseline CT were not considered
for switching. Most patients underwent a CDU to comple-
ment the CT scan when the decision to switch the patient
was made. All patients with suboptimal studies secondary
to anatomy or body habitus were not switched to CDU
surveillance. All medical records and imaging studies of
patients switched to CDU surveillance between 2003 and
2006 were retrospectively reviewed. Only patients with at
least 1 year follow-up on this surveillance schedule were
included and form the study population. The study proto-
col was reviewed and approved by the Institutional Review
Board of the University of Pittsburgh.
Duplex ultrasound. All duplex scans were performed
by an experienced registered vascular technologist in a fully
accredited office-based vascular laboratory. A LOGIQ 9
GE (General Electric Medical Systems, Milwaukee, Wis)
ultrasound machine and 3.5 MHz curvilinear transducer
were used. Patients were asked to fast overnight or at least
6 hours prior to their study. The CDU protocol included
longitudinal and transverse interrogation of the entire aor-
tic sac and iliac arteries. Peak systolic velocities were ob-
tained in the iliac vessels to assess for the presence of limb
flow anomalies. Endoleak detection as well as characteriza-
tion of the source was based on direct visualization and
spectral confirmation. Patients included in this study all had
adequate examinations with clear visualization of the en-
dograft, excluded sac, and iliac limbs.
CT scan. CT scans were routinely obtained at 1
month and 1 year after EVAR, and only selectively there-
after in patients on CDU surveillance. Helical CT was
performed with a Lightspeed QXi multi-detector-row CT
scanner (General Electric Medical Systems) from the dia-
phragm to the femoral heads. Contrast CT scans were
performed after a Smart Prep series and reconstructed with
a 1.3 or 2.5-mm slice thickness. Noncontrast studies were
obtained routinely and late imaging selectively to detect
slow endoleaks. Size measurements were all performed by
using an electronic caliper tool.
Applicability of the policy. Since criteria were grad-
ually expanded during the report period and many patients
were on a regulatory study protocol dictating CT scans for
up to 5 years, the applicability of the final policy to the
general EVAR population was not apparent from the study
group. To assess how many patients are suited for the
switch and how late after EVAR it could be implemented,
the clinical and follow-up imaging records of 200 consec-utive patients with available imaging, treated in 2004 and
2005 were reviewed for findings allowing a switch to CDU.
They form the applicability cohort.
Statistics. Baseline demographic, clinical, and proce-
dural characteristics were summarized as mean  standard
deviation (SD) and ranges for continuous variables and as
frequencies for categorical data. Kaplan-Meier methodol-
ogy was used to estimate survival, freedom from endoleaks,
and freedom from reintervention event rates.
RESULTS
One hundred eighty-four patients (159 males) were
switched to CDU surveillance between 2003 and 2006 and
were reviewed. The mean age was 73.9  7.1 years (range
52.6-93.4 years). Demographics and comorbidities are de-
tailed in Table I. All CDU examinations were technically
satisfactory for determination of aneurysm size and pres-
ence of endoleak. Mean follow-up on CDU only was 24
13 months (range 1-4 years).
All patients had undergone an EVAR at the Univer-
sity of Pittsburgh Medical Center. Endografts used were:
Ancure in 76 patients (Guidant, Menlo Park, Calif),
Zenith in 58 (Cook Medical, Bloomington, Ind), Ex-
cluder in 39 (Gore Medical, Flagstaff, Ariz), AneuRX in
7 (Medtronic, Santa Rosa, Calif), and Lifepath in 4
(Edwards Lifesciences, Irvine, Calif) (Table II). Initial
follow-up of these patients included x-rays and CT 1
month after EVAR, 6 months (for patients on proto-
cols), 12 months, and yearly thereafter. Following com-
mercial release of each graft the 6 months follow-up was
discontinued because of the low incidence of adverse
events detected.8 The CDU follow-up schedule was
initiated 34  24 months after EVAR (range 1-112
months). The mean AAA diameter at baseline was 54 
8 mm and had decreased to 40  11 mm before the
decision to implement CDU only surveillance. Forty
nine percent of patients had a collapsed aneurysm (4
cm) at the time of initiation of the new surveillance
Table I. Demographics and patient comorbidities
Characteristic
Percent or mean  SD (range)
(n  184)
Age (y) 73.9  7.1 (52.6 – 93.4)
Male 86.4%
Smoking status
Never 42.1%
Former 42.6%
Current 15.3%
History of diabetes mellitus 12.5%
Hypertension 90.8%
Dyslipidemia 69.6%
ESRD 3.3%
Coronary artery disease 63.0%
COPD 23.9%
ESRD, End stage renal disease; COPD, chronic obstructive pulmonary
disease.protocol. At last follow-up, the mean aneurysm diameter
VAR,
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diameter are detailed in Table II.
Endoleaks. Among the patients on CDU only surveil-
lance, a history of endoleak was present in 36 (19.5%). At
the time of the switch, 23 had spontaneously resolved or
were treated, and 13 were active persistent type II en-
doleaks with a stable or shrinking AAA sac.
Three new endoleaks were diagnosed during the CDU
only surveillance, only one presenting with sac enlarge-
ment. All prompted CT evaluation: one type II endoleak
with stable sac size could not be identified on the CT
obtained 3 months later, and two distal type I endoleaks
that required limb extension. All three patients had a prior
Ancure endograft. Two of these patients (1 Ancure, 1
AneuRx) had increased sac size with no endoleak visualized
on CDU or CT scan. The patient treated with a prior
Ancure was found to have a distal type I endoleak on
angiogram and required coil embolization and limb exten-
sion into the external iliac artery. This endoleak had not
been identified either on CDU nor CT imaging. No en-
doleak was identified on an angiography in the other pa-
tient without any further changes noted in sac diameter on
later follow-up.
Clinical outcomes. No patient had any clinical ad-
verse event during the period of observationNo ruptures or
graft occlusions were noted. There was one AAA related
death 3 days following graft explantation of an Ancure for
infection that was diagnosed 4 years after EVAR. There
were two additional deaths from lung cancer and two from
an acute coronary event with postinfarction heart failure
and a prolonged stay in the coronary care unit. After the
switch to CDU surveillance, the freedom from clinically
significant endoleaks was 96%, and from secondary inter-
ventions 95% at 48 months by life table method.
Clinical applicability. Among the 200 patients in the
applicability cohort, 86 patients (44%) were actually
switched to CDU surveillance. However, by applying the
current criteria to this group, 97%of patientswouldhave been
eligible for CDUonly surveillance by 3 years after EVAR. The
corresponding applicability at each yearly follow-up anniver-
sary is presented in the Fig. Many patients were not actually
switched in this cohort despite eligibility, frequently be-
cause of participation in regulatory trials withmandated CT
Table II. Graft specific aneurysm characteristics and follow
Graft type
N (%)
Baseline AAA size
(minor axis, mm)
AAA size at
surveillance (m
Ancure 76 (41) 53.7  7.6 36.5
AneuRx 7 (4) 53.5  4.2 36.9
Excluder 39 (21) 55.3  10.8 46.1
Lifepath 4 (2) 56.0  3.6 43.5
Zenith 58 (32) 52.4  6.9 41.1
CDU, Color-flow duplex ultrasound; AAA, abdominal aortic aneurysms; Efollow-up protocols, or surgeon preference.DISCUSSION
After EVAR, the need for lifelong surveillance drives
the search for an optimal means of monitoring endoleaks,
aneurysm size changes, migrations, structural failures, and
limb abnormalities. Ideally, one diagnostic modality would
identify any and all of these possible failure modes reliably.
Since the advent of EVAR, CT scanning has been the
mainstay of follow-up providing the most information
needed for this long-term surveillance. CT, however, suf-
fers from significant drawbacks including side effects re-
lated to contrast allergy and a significant radiation exposure
resulting in an increased risk of cancer.5 Moreover, the
nephrotoxic effect of iodinated contrast media used in CT
may contribute to a progressive deterioration in renal func-
tion over time reported in many patients after EVAR.6
Repeated frequent contrast exposure has been implicated in
chronic oxidative renal injury, contributing to a steady
decline in renal function. Finally, the high costs of CT
follow-up contribute a substantially to the financial disad-
vantage of EVAR compared with open repair.4
CDU is an attractive alternative imaging technique. It
is less invasive, rapidly available, less expensive, and does
not require repeated exposure to radiation or to contrast
agents. It has also been validated in the evaluation of
endoleaks as well as size changes after EVAR.9-14 En-
pre- and post-switch to CDU only follow-up
to CDU
axis, mm)
Time to CDU switch
post-EVAR (mo  SD)
(range)
Mean follow-up
post-switch (mo  SD)
(range)
52.1  23.3 (5-112) 33.8  11.1 (12-54)
48.8  27.4 (19-87) 21.1  15.7 (11-41)
.4 21.1  24.6 (1-98) 13.8  6.9 (12-31)
.2 44.7  4.1 (41-48) 16.1  1.1 (15-17.0)
.5 17.3  12.9 (1-75) 20.0  11.8 (13-44)
endovascular aneurysm repair.
Fig. Eligibility of a consecutive EVAR cohort for CDU surveil-
lance using the current switch criteria up to 3 years post repair.-up
switch
inor
 8.4
 6.5
 11
 13
 11doleaks may be the most frequent complication and consti-
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aneurysm sac. Although CDU has been shown to have an
excellent sensitivity and negative predictive value compared
with CT for the diagnosis of endoleak,7 these results have
not been uniformly reproduced.10,11 Our initial experience
with CDU in a hospital lab setting with old ultrasound
equipment was disappointing as we failed to establish good
correlation with CT for the detections of endoleaks.14 A
subsequent move to an office-based lab with modern
equipment and a stable experienced technologist pool im-
proved our results significantly. The current study was
performed entirely after the move to the office-based lab.
On the other hand, the correlation of CDU with CT in the
measurement of AAA sac diameter has been well estab-
lished and is a good surrogate for clinically significant
endoleaks.14 As more experience and late follow-up con-
tinue to be acquired, it is well established that late problems
following EVAR seem to present as endoleaks with sac
enlargement, or limb occlusion with claudication or critical
limb ischemia, both of which can be readily diagnosed by
CDU. Catastrophic events such as rupture frequently fol-
low poor compliance with follow-up schedules no matter
what the imaging technique is. Access to proper imaging
equipment and experienced technologists, quality control,
as well as the implementation of a standard imaging proto-
col for EVAR remain essential, however, for the safe adop-
tion of CDU follow-up.7,14
We followed a prudent and stepwise course in estab-
lishing duplex scan as a satisfactory EVAR follow-up mo-
dality. Although we started testing the hypothesis in a
highly selected group, this was not the case in patients
switched later, because our current criteria would apply to
the majority of patients by 3 years after EVAR. The latter
group may not have the same degree of evidence as the
initial one. However, we do not believe this affects the
conclusion that selected patients can be followed with
CDU as every patient had at least 1 year of follow-up safely
by CDU.
The time cutoff chosen for switch to CDU surveillance
is fairly arbitrary and is based on the institutional experience
with EVAR over a period of 7 years prior to the implemen-
tation of this follow-up regimen in addition to some regu-
latory requirements that prevented more patients from
being switched earlier. Our observation that patients with a
collapsed sac after EVAR are very stable, has been repro-
duced by others,7 and form a good subset for changing
imaging modalities. However, the applicability of such a
policy shift is more widespread as noted in the safety of the
switch in patients with no sac shrinking and even active type
II endoleaks. Although a persistent type II endoleak has
been postulated to eventually lead to pressurization of the
aneurysm sac in some patients,15 this is always associated
with increasing AAA diameter and can be readily diagnosed
by CDU. The 2-year cutoff for CDU surveillance in pa-
tients with a nonshrinking sac or an active but stable type II
endoleak is arbitrary but quite conservative, and could
probably be shortened as individual vascular laboratoriesbecome more comfortable with this technique and validate
their result with internal quality control.
As the new generation endografts in use continue to
generate longer term follow-up data attesting to the dura-
bility of the technique and the current devices, early switch
to CDU surveillance may gain wider acceptance. In fact,
most patients would be eligible for this regimen in most
practices since up to 97% of our patient population exam-
ined meets our switch criteria by 3 years after EVAR. A
change in clinical practice will therefore not only have a
significant impact on the cost of EVAR follow-up, but
could potentially obviate the steady deterioration in renal
function seen in this patient population, as well as the
possible risks of gastrointestinal and hematologic malig-
nancies due to radiation exposure.
It is important to note, that although we applied our
CDU surveillance policy to several devices, the device spe-
cific clinical results may dictate follow-up methods over
time. Most new generation devices seem to be associated
with less long-term failures andmay be better suited for this
imaging regimen than older devices.16 Similarly, patients
with initial suboptimal anatomy for EVAR may be at a
higher risk for future complications and be better followed
by CT at least intermittently alternating CDU with CT to
detect early changes in aortic neck anatomy and morphol-
ogy. Other patients who may not benefit from this follow-up
regimen include those being concomitantly followed for a
thoracic aortic aneurysm, and patients with excessive bowel
gas, ascites or a challenging body habitus.17
There were no adverse events related to the CDU
surveillance regimen, with no ruptures, device failures or
limb occlusions in the selected series. These findings paral-
lel those from other reports looking at the fate of endoleak
missed on ultrasound.10 All patients who developed a late
type I or type II endoleak either presented with sac enlarge-
ment or were diagnosed by direct visualization of the
endoleak channel. Only three patients developed a late
endoleak, and the high freedom from secondary interven-
tions attests to the safety of the utilized switch criteria. It is
important to note, however, that this study was not in-
tended to compare CDU andCT follow-upmodalities, and
the high freedom from endoleak reported points out that
this is a well selected group of patients to caution against
indiscriminate application of CDU only surveillance. Al-
though several other follow-up modalities have been pro-
posed for EVAR follow-up, CDU remains the simplest, the
least expensive, and the most expeditious, especially in an
office-based setting. Magnetic resonance angiography and
contrast enhanced CDU may be more sensitive for the
detection of endoleaks but suffer again from increased costs
and are less readily available.18 It is estimated that approx-
imately 65% of the total cost of EVAR follow-up is attrib-
utable to CT imaging.4 With longer follow-up and accrual
of more experience with this regimen, earlier switch to
CDU surveillance should have an even more significant
socioeconomic impact. The risks and cost of CT surveil-
lance have been used as a justification for limiting the use of
EVAR. A significant change is this follow-up policy, appli-
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fied use of EVAR for aneurysm treatment. Follow-up reg-
imens post-EVAR continue to be refined, with a clear trend
toward readily available office-based testing. The wider
application of aneurysm sac pressure sensors is expected to
enhance the safety of follow-up without CT but awaits
further confirmation.19 However, even if the setting of
collapsed nonpressurized sacs, it may be prudent to con-
tinue obtaining a CT scan every 5 years to detect new
remote aneurysms.20
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One important disadvantage of endovascular aneurysm repair
(EVAR) is the requirement for intense and lifelong surveillance. Dr
Chaer et al have put this assumption to the test in a retrospective
analysis of outcomes after EVAR in a selection of patients with a
shrinking or stable aneurysm sac in whom follow-up was switched
to color duplex ultrasound (CDU) imaging as the sole surveillance
method. They conclude that CDU-only surveillance is safe in these
patients and that it can be applied in almost all patients by 3 years
postoperatively. There are several reasons why these conclusions
must be interpreted with caution.
First, the reported safety is established in a highly selectedthe previous (elaborate) follow-up protocol and after having been
scrutinized and treated for endoleak: in short, successful EVAR
patients.
Furthermore, the selection criteria for CDU-only surveillance
were expanded after 1 year, skewing the study population. The
early switchers were predominantly long-term successful Ancure
(Guidant, Minneapolis, Minn) patients. Although this device is no
longer commercially available, it was shown to lead to early and
considerable sac shrinkage and to be durable. Conversely, the late
switchers were the patients with the newer endografts—mainly
Excluder (W. L. Gore and Assoc, Flagstaff, Ariz) and Zenith (Cook
Inc, Bloomington, Ind)—and therefore had shorter follow-up
